Cue Biopharma, Inc. (CUE)
Cue Biopharma, Inc. is a biotechnology company focused on developing immunotherapies that modulate the immune system by targeting specific T-cell pathways. Utilizing its proprietary drug discovery platform, Cue aims to create personalized treatments for cancer and other diseases by leveraging immune system modulation to enhance therapeutic outcomes.
Company News
Despite regulatory challenges and budget cuts, the oncology market is projected to reach US$900 billion by 2034, with several biotech companies advancing innovative cancer therapies and demonstrating promising clinical trial results.
Cue Biopharma received positive feedback from the FDA on its pre-IND briefing document for CUE-401, a first-in-class bispecific molecule designed to induce and expand regulatory T cells for the treatment of autoimmune diseases. The company plans to file an IND for CUE-401 after completing final enabling studies.
Xoma (XOMA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.